Huahai Pharmaceutical released its 2026 interim report. Total operating revenue was 4.913 billion yuan, net profit attributable to the parent company was 771 million yuan, and net cash inflow from operating activities was 1.098 billion yuan. The latest asset-liability ratio was 54.23 percent, up 1.28 percentage points from the same period last year. Gross margin was 58.41 percent, down 4.92 percentage points year on year. Return on equity was 7.88 percent. Diluted earnings per share were 0.52 yuan, total asset turnover was 0.23 times, and inventory turnover was 0.56 times. The number of shareholders was 83,300, and the top ten shareholders held 45.89 percent of total share capital.
Zhejiang Huahai Pharmaceutical Co LtdInterim report shows net profit of 771 million yuan, but gross margin declined and asset-liability ratio rose, mixed signals.